Angiotensin‐converting enzyme inhibitors increase anti‐fibrotic biomarkers in African Americans with left ventricular hypertrophy

• Published in: The journal of clinical hypertension (Greenwich, Conn.) Vol. 23; no. 5; pp. 1008 - 1016
• Main Authors: Romero, Cesar, Mathew, Shobi, Wasinski, Benjamin, Reed, Brian, Brody, Aaron, Dawood, Rachelle, Twiner, Michael J., McNaughton, Candace D., Fridman, Rafael, Flack, John M., Carretero, Oscar A., Levy, Phillip D.
• Format: Journal Article
• Language: English
• Published: United States John Wiley & Sons, Inc 01.05.2021; John Wiley and Sons Inc; Wiley
• Subjects: ACE inhibitors; Ac‐SDKP; Adult; African American; African Americans; Angiotensin-Converting Enzyme Inhibitors - therapeutic use; Antihypertensives; Anti‐fibrotic Biomarkers; Biomarkers; Blood pressure; Cardiovascular disease; Cocaine; Collagen; Enzymes; Fibroblasts; Heart attacks; Humans; Hypertension; Hypertension - drug therapy; Hypertrophy, Left Ventricular - drug therapy; left ventricular hypertrophy; Mental disorders; Middle Aged; MMP‐1; Original Paper; Patients; Peptides; Vitamin D; collagen; Ac-SDKP; left ventricular hypertrophy; MMP-1; ACE inhibitors; African American

Angiotensin‐converting enzyme inhibitors (ACEi) are part of the indicated treatment in hypertensive African Americans. ACEi have blood pressure‐independent effects that may make them preferred for certain patients. We aimed to evaluate the impact of ACEi on anti‐fibrotic biomarkers in African Americ...